Ganga Pharma.

Why is Ganga Pharmaceuticals Ltd falling/rising?

As of 01-Sep, Ganga Pharmaceuticals Ltd's stock price is at 12.00, unchanged from the previous session, with stagnant performance over the past week and month. Despite the broader market decline, increased investor participation and stable price suggest a cautious outlook for the stock.

As of 01-Sep, Ganga Pharmaceuticals Ltd's stock price is currently at 12.00, showing no change (0.00%) from the previous trading session. The stock's performance over the past week and month has been stagnant, with a return of +0.00% in both periods, while the benchmark Sensex has declined by -0.92% and -1.47%, respectively. This indicates that the stock is performing in line with the sector, as it has not experienced any price movement despite the broader market's downward trend.<BR><BR>Additionally, the stock has shown erratic trading, having not traded on 5 out of the last 20 days, which may contribute to its stability in price. The moving averages indicate that the stock is currently higher than its 200-day moving average but lower than its 5-day, 20-day, 50-day, and 100-day moving averages, suggesting a mixed short-term performance relative to longer-term trends.<BR><BR>Investor participation appears to be increasing, as evidenced by a significant rise in delivery volume, which increased by 66.67% against the 5-day average. This uptick in trading activity could indicate growing interest among investors, potentially supporting the stock's price stability.<BR><BR>Overall, while Ganga Pharmaceuticals Ltd's stock price is not rising or falling at this moment, the combination of stable performance relative to the market, increased investor participation, and erratic trading patterns suggests a cautious outlook for the stock.

Who are in the management team of Ganga Pharma.?

The management team of Ganga Pharma includes Sanjay Vyankatesh Kulkarni (Chairman), Bharat Brijmohan Sharma (Managing Director & CEO), Srijna Sharma (Whole-time Director), and independent directors Sachin Chandrakant Chavan and Chetan Bhikhubhai Patel.

The management team of Ganga Pharma includes the following individuals:<BR><BR>1. **Sanjay Vyankatesh Kulkarni** - Chairman & Non-Executive Director<BR>2. **Bharat Brijmohan Sharma** - Managing Director & CEO<BR>3. **Srijna Sharma** - Whole-time Director<BR>4. **Sachin Chandrakant Chavan** - Independent Director<BR>5. **Chetan Bhikhubhai Patel** - Independent Director<BR><BR>If you have any more questions about Ganga Pharma or its operations, feel free to ask!

What does Ganga Pharma. do?

Ganga Pharmaceuticals Ltd manufactures and trades Ayurvedic pharmaceuticals and operates in the micro-cap segment of the Pharmaceuticals & Biotechnology industry. As of September 2024, it reported net sales of 1 Cr and a market cap of INR 7 Cr.

Overview: <BR>Ganga Pharmaceuticals Ltd is engaged in the manufacturing and trading of pharmaceuticals and allied products, specifically Ayurveda, and operates within the micro-cap segment of the Pharmaceuticals & Biotechnology industry.<BR><BR>History: <BR>Ganga Pharmaceuticals Ltd was incorporated as a Public Limited Company in August 1994. The company took over Ganga Pharmaceuticals, a proprietary concern owned by the same promoter, in April 1995. The latest quarterly results reported net sales and net profit for September 2024.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Cr (Quarterly Results - Sep 2024) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Sep 2024) <BR>Market-cap value: INR 7 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 89.00 <BR>Industry P/E: 24 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.19 <BR>Return on Equity: 0.97% <BR>Price to Book: 0.86 <BR><BR>Contact Details: <BR>Address: Gangatat Dhanvantri Marg, Gopcharpada Virar (E) Palghar Maharashtra : 401305 <BR>Tel: 91-250-6098333/444 <BR>Email: ayurvedganga@gmail.com <BR>Website: http://www.ayurvedganga.com

Who are the peers of the Ganga Pharma.?

Ganga Pharma's peers include Unjha Formulations, Ortin Global, Beryl Drugs, Vivanza Biosciences, Brawn Biotech, Decipher Labs, Fabino Enterprises, and Shyama Computro. Unjha Formulations shows excellent management risk and the highest 1-year return at 10.70%, while Ganga Pharma and most peers exhibit average to below-average management risk and growth.

Peers: Ganga Pharma's peers include Unjha Formul., Ortin Global, Beryl Drugs, Vivanza Biosci., Brawn Biotech, Decipher Labs, Fabino Enter, and Shyama Computro.<BR><BR>Quality Snapshot: Excellent management risk is observed at Unjha Formul., while Average management risk is found at Ganga Pharma and the rest. Below Average management risk is noted for Ortin Global, Beryl Drugs, Vivanza Biosci., Brawn Biotech, Decipher Labs, and Fabino Enter. Growth is Below Average for Ortin Global, Beryl Drugs, Brawn Biotech, Decipher Labs, and Fabino Enter, while Ganga Pharma and the rest also exhibit Below Average growth. Average growth is seen at Vivanza Biosci. Capital Structure is Good at Unjha Formul., Average at Ganga Pharma, and Below Average for Ortin Global, Beryl Drugs, Vivanza Biosci., Brawn Biotech, Decipher Labs, and Fabino Enter.<BR><BR>Return Snapshot: Unjha Formul. has the highest 1-year return at 10.70%, while Decipher Labs has the lowest at -48.50%. Ganga Pharma's 1-year return is not available for comparison. Additionally, the six-month returns for Ortin Global, Vivanza Biosci., Decipher Labs, and Brawn Biotech are negative.

How big is Ganga Pharma.?

As of 31st August, Ganga Pharmaceuticals Ltd has a market capitalization of 7.00 Cr, with recent net sales of 5.49 Cr and a net profit of 0.16 Cr. The company has shareholder's funds of 7.13 Cr and total assets of 8.97 Cr as of March 2025.

As of 31st August, Ganga Pharmaceuticals Ltd has a market capitalization of 7.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, Ganga Pharmaceuticals Ltd reported Net Sales of 5.49 Cr and a Net Profit of 0.16 Cr.<BR><BR>For the latest annual period ending in March 2025, the company has Shareholder's Funds amounting to 7.13 Cr and Total Assets of 8.97 Cr.

Which are the latest news on Ganga Pharma.?

When is the next results date for Ganga Pharmaceuticals Ltd?

The next results date for Ganga Pharmaceuticals Ltd is 21 May 2026.

The next results date for Ganga Pharmaceuticals Ltd is scheduled for 21 May 2026.

How has been the historical performance of Ganga Pharma.?

Ganga Pharma's historical performance shows stable share capital and a slight increase in reserves and shareholder's funds, with reduced long-term borrowings and improved total assets. Overall, the company reflects financial stability with low debt levels and positive cash flow from investing activities.

Answer:<BR>The historical performance of Ganga Pharma shows a consistent trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Ganga Pharma's share capital remained stable at Rs 4.84 crore from March 2024 to March 2025, while total reserves increased slightly from Rs 1.59 crore in March 2024 to Rs 1.67 crore in March 2025. Shareholder's funds also saw a modest rise, reaching Rs 7.13 crore in March 2025, up from Rs 7.05 crore the previous year. Long-term borrowings decreased from Rs 0.39 crore in March 2024 to Rs 0.23 crore in March 2025, indicating a reduction in debt levels. Total liabilities increased to Rs 8.97 crore in March 2025 from Rs 8.65 crore in March 2024, while total assets also rose to Rs 8.97 crore in March 2025 from Rs 8.65 crore in March 2024. The book value per share adjusted slightly to Rs 13.46 in March 2025 from Rs 13.30 in March 2024. Cash flow from operating activities remained at zero across the years, with cash flow from investing activities showing a positive inflow of Rs 1 crore in March 2025, contrasting with no activity in the previous year. Overall, Ganga Pharma's financial position reflects stability with slight improvements in reserves and assets, while maintaining low debt levels.

Has Ganga Pharma. declared dividend?

No Dividend History Available

Who are the top shareholders of the Ganga Pharma.?

The top shareholders of Ganga Pharma include Sharma Bharat B with 30.12%, Lenus Finvest Private Limited at 7.75%, and individual investors holding 35.07%. There are no mutual funds or foreign institutional investors currently involved.

The top shareholders of Ganga Pharma include the promoters, with Sharma Bharat B holding the largest share at 30.12%. The highest public shareholder is Lenus Finvest Private Limited, which owns 7.75%. Additionally, individual investors collectively hold 35.07% of the company's shares. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.